MARCH Renal Substudy
Summary
Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV. Antiretroviral therapy associated renal dysfunction has been predominantly described in terms of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur in the absence of significant reductions in eGFR. This substudy is an exploration of changes in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART).
Timeline
- Start
- 2012-06
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Maraviroc | Other / unclassified | — | — |
| Comparator | Abacavir | Other / unclassified | — | — |
| Comparator | Atazanavir | Other / unclassified | — | — |
| Comparator | Darunavir | Small molecule | — | — |
| Comparator | Fosamprenavir | Small molecule | — | — |
| Comparator | Lamivudine | Other / unclassified | — | — |
| Comparator | Lopinavir | Other / unclassified | — | — |
| Comparator | Ritonavir | Other / unclassified | — | — |
| Comparator | Tenofovir | Small molecule | — | — |
| Comparator | Zidovudine | Small molecule | — | — |
| Comparator | emtricitabine | Other / unclassified | — | — |